Endometrial cancer cell (EC cell)

Endometrial cancer cells are the malignant cells originating from the inner lining of the uterus, and they represent the most prevalent gynecological malignancy in developed countries. These cells are broadly categorized into two types: Type I (endometrioid), which are typically hormone-sensitive and frequently harbor PTEN or PIK3CA mutations, and Type II (non-endometrioid, such as serous), which are more aggressive and often characterized by p53 mutations and HER2 amplification. While the cells themselves are the pathological entity, therapeutic interventions target specific molecular alterations and pathways within these cells to inhibit their growth and survival. Common molecular targets include the PI3K/AKT/mTOR signaling pathway, DNA mismatch repair systems, and various hormone receptors. Modern treatments utilize immune checkpoint inhibitors to exploit the high mutational burden of these cells, particularly those with microsatellite instability, alongside targeted kinase inhibitors and traditional endocrine therapies.

Other names

Uterine cancer cellEndometrial adenocarcinoma cellUterine corpus carcinoma cellEndometrial carcinoma cell

Therapeutic agents targeting endometrial cancer cells function through diverse mechanisms, including immune checkpoint inhibition (PD-1/PD-L1 blockade), multi-kinase inhibition (targeting VEGFR, FGFR, and PDGFR), mTOR pathway inhibition, progesterone receptor agonism to induce differentiation/apoptosis, and cytotoxic DNA damage via platinum-based alkylation and microtubule stabilization.